Literature DB >> 7974675

Type 1 reactions in leprosy, neuritis and steroid therapy: the impact of the human immunodeficiency virus.

R Bwire1, H J Kawuma.   

Abstract

The incidence of type 1 reactions and neuritis among HIV seronegative and HIV seropositive leprosy patients was investigated. HIV seropositivity was associated with an increased incidence of type 1 reactions among multibacillary (MB) patients, which were observed in 9 of 12 seropositive MB patients and in 8 of 40 HIV seronegative MB patients (P < 0.0005). Similarly, the incidence of neuritis was significantly increased among the HIV seropositive MB patients, of whom 8 developed acute neuritis compared to 3 of the HIV seronegative patients (P < 0.0005). There was no significant difference between the numbers of paucibacillary HIV seropositive and HIV seronegative patients who developed these complications. Both the HIV seronegative and HIV seropositive patients showed a similar response to steroid therapy for the management of acute neuritis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7974675     DOI: 10.1016/0035-9203(94)90098-1

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  3 in total

1.  Late reversal reaction after 10 years of adequately treated leprosy.

Authors:  A K Thacker; P Kumar; R D Mukhija; S P Sharma
Journal:  Postgrad Med J       Date:  1997-11       Impact factor: 2.401

Review 2.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

3.  HIV-M. leprae interaction: can HAART modify the course of leprosy?

Authors:  Euzenir Nunes Sarno; Ximena Illarramendi; José A Costa Nery; Anna M Sales; Maria C Gutierrez-Galhardo; Maria L Fernandes Penna; Elizabeth Pereira Sampaio; Gilla Kaplan
Journal:  Public Health Rep       Date:  2008 Mar-Apr       Impact factor: 2.792

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.